SPA
RGNX icon

Sherbrooke Park Advisers’s Regenxbio RGNX Stock Holding History

Sherbrooke Park Advisers’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,005
Closed -$125K – 472
2025
Q3 		$125K Sell
13,005
-15,634
-55% -$138K 0.06% 431
2025
Q2 		$235K Buy
28,639
+4,234
+17% +$35.4K 0.1% 355
2025
Q1 		$174K Buy
24,405
+75
+0.3% +$558 0.08% 447
2024
Q4 		$188K Sell
24,330
-5,377
-18% -$50.5K 0.06% 600
2024
Q3 		$312K Buy
29,707
+13,850
+87% +$169K 0.07% 549
2024
Q2 		$186K Buy
+15,857
New +$247K 0.03% 780

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sherbrooke Park Advisers's RGNX Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of Regenxbio (RGNX) in Q4 2025, closing a stake of 13,005 shares — an estimated $125K sold.

Sherbrooke Park Advisers first reported a position in RGNX in Q2 2024 and held it in 6 quarters. The position peaked at $312K in Q3 2024. 174 funds tracked by Wall St. Rank hold RGNX as of Q4 2025.

  • Sherbrooke Park Advisers reported no remaining Regenxbio position as of Q4 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 13,005 Regenxbio shares in Q4 2025, an estimated $125K.
  • Sherbrooke Park Advisers first reported a position in Regenxbio in Q2 2024 and held it in 6 quarters.
  • Sherbrooke Park Advisers's Regenxbio position peaked at $312K in Q3 2024.
  • 174 funds tracked by Wall St. Rank held Regenxbio as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.